Back to Search Start Over

Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial

Authors :
Patrick M. McCarthy
Brian Whisenant
Anita W. Asgar
Gorav Ailawadi
James Hermiller
Mathew Williams
Andrew Morse
Michael Rinaldi
Paul Grayburn
James D. Thomas
Randolph Martin
Federico M. Asch
Yu Shu
Kartik Sundareswaran
Neil Moat
Saibal Kar
Source :
Journal of the American Heart Association. 12
Publication Year :
2023
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2023.

Abstract

Background The current standard of care for the treatment of patients with primary mitral regurgitation (MR) is surgical mitral valve repair. Transcatheter edge‐to‐edge repair with the MitraClip device provides a less invasive treatment option for patients with both primary and secondary MR. Worldwide, >150 000 patients have been treated with the MitraClip device. However, in the United States, MitraClip is approved for use only in primary patients with MR who are at high or prohibitive risk for mitral valve surgery. The REPAIR MR (Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery) trial is designed to compare early and late outcomes associated with transcatheter edge‐to‐edge repair with the MitraClip and surgical repair of primary MR in older or moderate surgical risk patients. Methods and Results The REPAIR MR trial is a prospective, randomized, parallel‐controlled, open‐label multicenter, noninferiority trial for the treatment of severe primary MR (verified by an independent echocardiographic core laboratory). Patients with severe MR and indications for surgery because of symptoms (New York Heart Association class II–IV), or without symptoms with left ventricular ejection fraction ≤60%, pulmonary artery systolic pressure >50 mm Hg, or left ventricular end‐systolic diameter ≥40 mm are eligible for the trial provided they meet the moderate surgical risk criteria as follows: (1) ≥75 years of age, or (2) if Conclusions The REPAIR MR trial will determine the safety and effectiveness of transcatheter edge‐to‐edge repair with the MitraClip in patients with primary MR who are at moderate surgical risk and are candidates for surgical MV repair. The trial will generate contemporary comparative clinical evidence for the MitraClip device and surgical MV repair. Registration https://clinicaltrials.gov/ct2/show/NCT04198870 ; NCT04198870.

Details

ISSN :
20479980
Volume :
12
Database :
OpenAIRE
Journal :
Journal of the American Heart Association
Accession number :
edsair.doi...........550c6781a6bc265b065e8628ccd2f8c2